Kolvenbach R, Kreissig C, Ludwig E, Cagiannos C
Department of Vascular Surgery and Endovascular Therapy, Augusta Hospital, Duesseldorf, Germany.
J Cardiovasc Surg (Torino). 2007 Feb;48(1):39-44.
The following paper gives an overview of the current status of stem cell use in vascular medicine. The role of endothelial progenitor cells (EPCs) is discussed. Different approaches to use cellular based concepts are outlined: among these are the treatment of patients with critical ischemia with bone marrow derived mononuclear cells as well as our own experience with purified and highly selected CD133 and CD34 cells. The pro and cons of these different treatment regimens are discussed. An outlook is given discussing a combination of gene therapy and stem cell injections. The clinical and laboratory results of 15 patients with end-stage critical ischemia are discussed with implications for future clinical trials. We conclude that, despite all open questions, the outlook for EPC-based therapies for tissue ischemia and blood vessel repair appears promising.
以下论文概述了干细胞在血管医学中的应用现状。讨论了内皮祖细胞（EPCs）的作用。概述了使用基于细胞概念的不同方法：其中包括用骨髓来源的单核细胞治疗严重缺血患者以及我们自己使用纯化和高度筛选的CD133和CD34细胞的经验。讨论了这些不同治疗方案的利弊。展望了基因治疗与干细胞注射相结合的前景。讨论了15例终末期严重缺血患者的临床和实验室结果及其对未来临床试验的影响。我们得出结论，尽管仍有诸多未解决的问题，但基于EPC的组织缺血和血管修复治疗前景似乎很乐观。
